In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioSante Pharmaceuticals Inc.

Division of ANI Pharmaceuticals Inc.

Latest From BioSante Pharmaceuticals Inc.

AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Research & Development Deals

FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs

Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.

Clinical Trials Drug Approval Standards

Aduro gets $200m as Novartis steps up immuno-oncology

Aduro Biotech has secured a $200m upfront payment from Novartis as the latter steps up its activity in immunotherapy for cancer. The deal brings Novartis an early-stage immuno-oncology platform targeting the Stimulator of Interferon Genes (STING) pathway, adding to its ongoing programs using chimeric antigen receptor T-cell (CART) technology and checkpoint inhibitors.

Cancer Japan

Palatin ploughs barren female sexual dysfunction field

New Jersey's Palatin Technologies has initiated a pivotal Phase III trial for its female sexual dysfunction (FSD) drug bremelanotide, ploughing ahead in what appears to be a difficult area. Companies which have attempted to till this field have typically found their crops lacking, and Palatin itself is no stranger to the FSD drought.

Gastrointestinal Gynecology & Urology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ben-Abraham Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ANI Pharmaceuticals Inc.
  • Senior Management
  • Stephen M Simes, Pres. & CEO
    Joanne Zborowski, MD, PhD, VP, Clin. Dev.
    Robert Schrepfer, VP, New Bus. Dev. & Contract Mfg.
  • Contact Info
  • BioSante Pharmaceuticals Inc.
    Phone: (847) 478-0500
    111 Barclay Blvd.
    Ste. 1280
    Lincolnshire, IL 60069